Relapsed/Refractory Immune-mediated Kidney Disease Clinical Trials in Shanghai

An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease